Instruction 1(b).

### FORM 5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

# ANNUAL STATEMENT OF CHANGES IN BENEFICIAL **OWNERSHIP**

	OMB APPROVAL									
	OMB Number:	3235-0362								
	Estimated average burden									
-	hours per response:	1.0								

Form 3	Holdings Report	rted.															· ·		
Form 4	Transactions R	eported.	Fil	ed pursuant to or Sectior								f 1934							
Name and Address of Reporting Person*      CARLOZZI GERARD S      (First) (Middle)				INTEG CORP	2. Issuer Name and Ticker or Trading Symbol INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]  3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)								5. Relationship of Reporting (Check all applicable) Director X Officer (give title below)				Person(s) to Issuer  10% Owner Other (specify below)		
				-	12/31/2007  4. If Amendment, Date of Original Filed (Month/Day/Year)						6.	Executive VP and COO  6. Individual or Joint/Group Filing (Check Applicable							
(Street) (City)	-	Transmining Date of Original Filed (Month Day) Teal)							X Form filed by One Reporting Person Form filed by More than One Reporting Person										
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Da if any (Month/Day/Y	Code			4. Securities Acquired (A) or Dispose (D) (Instr. 3, 4 and 5)			Disposed (	Secui Benet		es	6. Ownership Form: Direct (D) or		7. Nature of Indirect Beneficial Ownership		
				(Monthibay/Tear)		3,				(A) or (D)	Pı	rice	li Y	Issuer's Fiscal Year (Instr. 3 and 4)		Indirect (I) (Instr. 4)		(Instr. 4)	
Common Stock			12/31/2007		<b>J</b> (1)		)	5	96	A		\$39.8335		3,085		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year) (Month/Day/Year) Transaction Code (Instr. 8) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expi (Mor	Date Exercisable and piration Date onth/Day/Year)  te		Am Sec Und Der Sec and	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)  Amount or Numbion of Title		nt er		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownershi t (Instr. 4)	t I		

### **Explanation of Responses:**

1. Shares acquired pursuant to Integra LifeSciences's Stock Purchase Plan under section 423 of the Internal Revenue Code of 1986, as amended, in a transaction exempt under Rule 16b-3.

# Remarks:

Power of Attorney Attached.

/s/ Kathryn Lamping, Attorney-in-Fact

02/01/2008

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

#### POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby authorizes Wilma Davis, Richard Gorelick, Kathryn Lamping and Richard Porter to execute for and on behalf of the undersigned Forms 3, 4 and 5, and any amendments thereto, and cause such form(s) to be filed with the United States Securities and Exchange Commission pursuant to Section 16(a) of the Securities Act of 1934, relating to the undersigned's beneficial ownership of securities in Integra LifeSciences Holdings Corporation (the "Company"). The undersigned also authorizes the above persons to execute for and on behalf of the undersigned any Form ID or similar document required to obtain or renew Securities and Exchange Commission electronic filings codes and passwords and cause such form(s) to be submitted to and/or filed with the Securities and Exchange Commission. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 29th day of October, 2007.

/s/ Gerard S. Carlozzi

Print Name: Gerard S. Carlozzi